Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Granulocyte-colony stimulating factor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| G-CSF + plerixafor | EXPERIMENTAL | Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses. |
| G-CSF + Placebo | PLACEBO_COMPARATOR | Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses. |
| Name | Type | Description |
|---|---|---|
| Granulocyte-colony stimulating factor (G-CSF) | DRUG | 10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection |
| Plerixafor | DRUG | 0.24 mg/kg/day subcutaneous injection |
| Placebo | DRUG | 0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection |
Inclusion Criteria: * Has a biopsy-confirmed diagnosis of NHL * Is in first or second complete remission or partial remission, defined for the purpose of this study as complete or partial response following first- or second-line therapy * Treatment with an autologous peripheral HSC transplant is pl...
Granulocyte-colony stimulating factor (G-CSF) is being studied for use in Non-Hodgkin's Lymphoma to mobilize and collect CD34+ cells for autologous transplantation. It is being evaluated in combination with plerixafor in a Phase 3 clinical trial.
Granulocyte-colony stimulating factor is being developed by Sanofi, a company traded under the ticker SNY. The drug is currently in Phase 3 clinical development for Non-Hodgkin's Lymphoma.
Granulocyte-colony stimulating factor is in Phase 3 clinical development. It is an investigational drug being studied for Non-Hodgkin's Lymphoma and has not been approved by regulatory authorities for this indication.
Granulocyte-colony stimulating factor is being studied in clinical trial NCT01767714, a Phase 3 study evaluating plerixafor plus G-CSF to mobilize and collect CD34+ cells in Non-Hodgkin's Lymphoma patients for autologous transplantation. This trial has been completed.
Granulocyte-colony stimulating factor works by stimulating the production and release of neutrophils from the bone marrow. In the context of Non-Hodgkin's Lymphoma, it is used to mobilize hematopoietic stem cells, such as CD34+ cells, into the peripheral blood for collection and subsequent autologous transplantation.